AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. HSDT
  4. [S-8] Helius Medical Technologies, Inc. Employee Benefit Plan Registration

[S-8] Helius Medical Technologies, Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

WD-40 Company (NASDAQ: WDFC) reported solid year-to-date results for FY-2025 Q3 (nine months ended 31-May-2025), highlighted by topline growth, margin expansion and a one-off tax benefit.

Income statement: Net sales rose 5 % year-to-date to $456.5 million (Q3 alone +1 % to $156.9 million), driven mainly by price/mix and volume recovery in maintenance products. Gross profit climbed 9 % to $251.9 million, lifting gross margin 210 bp to 55.2 % (Q3 margin 56.1 %). Operating expenses grew 11 % (higher SG&A and advertising), but operating income still advanced 5 % to $75.8 million. A $11.9 million release of an uncertain tax position cut the effective tax rate to 5.9 %, pushing net income up 32 % to $69.8 million and diluted EPS to $5.13 (vs. $3.88).

Segment trends:

  • Americas revenue +5 % YTD to $213.1 million, supported by WD-40 Multi-Use (+6 %) and Specialist lines (+9 %).
  • EIMEA revenue +7 % to $173.8 million; strong price/mix and volume recovery offset Q3 currency headwinds.
  • Asia-Pacific essentially flat at $69.6 million; modest growth in Specialist offset softness in other maintenance lines.

Balance sheet & cash flow: Cash rose to $51.7 million; net cash from operations was $58.0 million. Total debt stands at $95.8 million (net leverage <1脳 EBITDA); all covenants met. Shareholder returns totaled $47.2 million (dividends $37.5 million; buybacks $9.7 million). The existing $50 million repurchase authorization was extended one year to 31-Aug-2026; $32.2 million remains.

Strategic actions: Certain homecare & cleaning brands (inventory, goodwill and intangibles worth $9.3 million) were classified as held for sale, signalling continued portfolio focus on core maintenance products. The UK subsidiary changed functional currency to the Euro, simplifying reporting.

Guidance/Outlook: Management reiterated its four-by-four strategic framework, emphasising gross margin above 55 % and continued investment in brand building. Inflation, FX volatility and HCCP divestiture timing remain key watch-points.

WD-40 Company (NASDAQ: WDFC) ha riportato risultati solidi nei primi nove mesi dell'anno fiscale 2025 (terminati il 31 maggio 2025), evidenziando crescita dei ricavi, espansione dei margini e un beneficio fiscale una tantum.

Conto economico: Le vendite nette sono aumentate del 5% da inizio anno a 456,5 milioni di dollari (solo nel terzo trimestre +1% a 156,9 milioni di dollari), trainate principalmente da prezzo/mix e ripresa dei volumi nei prodotti per la manutenzione. Il margine lordo 猫 cresciuto del 9% a 251,9 milioni di dollari, portando il margine lordo a 55,2% (+210 punti base) (margine Q3 56,1%). Le spese operative sono aumentate dell'11% (a causa di maggiori SG&A e pubblicit脿), ma l'utile operativo 猫 comunque salito del 5% a 75,8 milioni di dollari. Un rilascio di 11,9 milioni di dollari relativo a una posizione fiscale incerta ha ridotto l'aliquota fiscale effettiva al 5,9%, facendo salire l'utile netto del 32% a 69,8 milioni di dollari e l'EPS diluito a 5,13 dollari (da 3,88).

Tendenze per segmento:

  • Ricavi Americas +5% da inizio anno a 213,1 milioni di dollari, supportati da WD-40 Multi-Use (+6%) e linee Specialist (+9%).
  • Ricavi EIMEA +7% a 173,8 milioni di dollari; forte prezzo/mix e recupero dei volumi hanno compensato le difficolt脿 valutarie del Q3.
  • Asia-Pacific sostanzialmente stabile a 69,6 milioni di dollari; moderata crescita nel segmento Specialist ha compensato la debolezza in altre linee di manutenzione.

Stato patrimoniale e flussi di cassa: La liquidit脿 猫 salita a 51,7 milioni di dollari; il flusso di cassa netto da attivit脿 operative 猫 stato di 58,0 milioni di dollari. Il debito totale 猫 pari a 95,8 milioni di dollari (leva netta inferiore a 1脳 EBITDA); tutti i covenant sono rispettati. I ritorni agli azionisti hanno totalizzato 47,2 milioni di dollari (dividendi 37,5 milioni; riacquisti 9,7 milioni). L'autorizzazione esistente per riacquisto di 50 milioni 猫 stata estesa di un anno fino al 31 agosto 2026; rimangono 32,2 milioni disponibili.

Azioni strategiche: Alcuni marchi di homecare e pulizia (inventario, avviamento e intangibili per 9,3 milioni di dollari) sono stati classificati come held for sale, segnalando un focus continuo sul portafoglio di prodotti core per la manutenzione. La controllata UK ha cambiato la valuta funzionale in euro, semplificando la reportistica.

Previsioni/Outlook: Il management ha ribadito il quadro strategico 鈥渜uattro per quattro鈥�, sottolineando l'obiettivo di un margine lordo superiore al 55% e il continuo investimento nel brand building. Inflazione, volatilit脿 valutaria e tempistica della cessione HCCP restano punti chiave da monitorare.

WD-40 Company (NASDAQ: WDFC) report贸 resultados s贸lidos en lo que va del a帽o para el tercer trimestre del a帽o fiscal 2025 (nueve meses terminados el 31 de mayo de 2025), destacando crecimiento en ingresos, expansi贸n de m谩rgenes y un beneficio fiscal extraordinario.

Estado de resultados: Las ventas netas aumentaron un 5% en lo que va del a帽o a 456.5 millones de d贸lares (solo en el tercer trimestre +1% a 156.9 millones), impulsadas principalmente por precio/mezcla y recuperaci贸n de volumen en productos de mantenimiento. La utilidad bruta subi贸 un 9% a 251.9 millones de d贸lares, elevando el margen bruto 210 puntos base a 55.2% (margen Q3 56.1%). Los gastos operativos crecieron un 11% (mayores SG&A y publicidad), pero el ingreso operativo avanz贸 un 5% a 75.8 millones. Una liberaci贸n de 11.9 millones de d贸lares relacionada con una posici贸n fiscal incierta redujo la tasa efectiva de impuestos al 5.9%, impulsando la utilidad neta un 32% a 69.8 millones y el EPS diluido a 5.13 d贸lares (vs. 3.88).

Tendencias por segmento:

  • Ingresos en Americas +5% YTD a 213.1 millones, apoyados por WD-40 Multi-Use (+6%) y l铆neas Specialist (+9%).
  • Ingresos en EIMEA +7% a 173.8 millones; fuerte precio/mezcla y recuperaci贸n de volumen compensaron los vientos en contra cambiarios del Q3.
  • Asia-Pac铆fico pr谩cticamente plano en 69.6 millones; crecimiento modesto en Specialist compens贸 debilidad en otras l铆neas de mantenimiento.

Balance y flujo de caja: El efectivo aument贸 a 51.7 millones; el flujo neto de operaciones fue de 58.0 millones. La deuda total es de 95.8 millones (apalancamiento neto <1脳 EBITDA); se cumplieron todos los convenios. Retornos a accionistas totalizaron 47.2 millones (dividendos 37.5 millones; recompras 9.7 millones). La autorizaci贸n existente para recompra de 50 millones se extendi贸 un a帽o hasta el 31 de agosto de 2026; quedan 32.2 millones disponibles.

Acciones estrat茅gicas: Algunas marcas de cuidado del hogar y limpieza (inventario, plusval铆a e intangibles por 9.3 millones) fueron clasificadas como held for sale, indicando un enfoque continuo en el portafolio principal de productos de mantenimiento. La filial del Reino Unido cambi贸 su moneda funcional al euro, simplificando la presentaci贸n de informes.

Perspectivas: La direcci贸n reafirm贸 su marco estrat茅gico cuatro por cuatro, enfatizando un margen bruto superior al 55% y la inversi贸n continua en construcci贸n de marca. La inflaci贸n, volatilidad cambiaria y el momento de la desinversi贸n de HCCP siguen siendo puntos clave a vigilar.

WD-40 Company (NASDAQ: WDFC)電� 2025 須岅硠鞐半弰 3攵勱赴(2025雲� 5鞗� 31鞚� 膦呺 9臧滌洈臧�) 瓴碃頃� 鞐办磮 雸勳爜 鞁れ爜鞚� 氚滍憸頄堨溂氅�, 毵れ稖 靹膘灔, 毵堨 頇曤寑 氚� 鞚柬殞靹� 靹戈笀 順滍儩鞚� 霊愲摐霟鞀惦媹雼�.

靻愳澋瓿勋偘靹�: 靾滊Г於滌潃 鞐办磮 雽�牍� 5% 歃濌皜頃� 4鞏� 5,650毵� 雼煬毳� 旮半頄堨溂氅�(3攵勱赴 雼弲鞙茧電� 1% 歃濌皜頃� 1鞏� 5,690毵� 雼煬), 欤茧 臧�瓴�/氙轨姢鞕� 鞙犾氤挫垬 鞝滍拡鞚� 氍茧焿 須岆车鞐� 頌橃瀰鞐堨姷雼堧嫟. 毵れ稖齑濎澊鞚奠潃 9% 歃濌皜頃� 2鞏� 5,190毵� 雼煬搿�, 毵れ稖齑濎澊鞚惦鞚� 210bp 靸侅姽頃� 55.2%(3攵勱赴 毵堨 56.1%)毳� 旮半頄堨姷雼堧嫟. 鞓侅梾牍勳毄鞚� 11% 歃濌皜(韺愲Г甏�毽箘 氚� 甏戧碃牍� 歃濌皜)頄堨溂雮� 鞓侅梾鞚挫澋鞚� 5% 歃濌皜頃� 7,580毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 攵堩檿鞁ろ暅 靹鸽 鞙勳箻 頃挫唽搿� 鞚疙暅 1,190毵� 雼煬鞚� 鞚柬殞靹� 靹戈笀 順滍儩鞚� 鞙犿毃靹胳湪鞚� 5.9%搿� 雮稊鞏� 靾滌澊鞚奠潉 32% 歃濌皜頃� 6,980毵� 雼煬 氚� 頋劃 欤茧嫻靾滌澊鞚�(EPS)鞚� 5.13 雼煬(旮办〈 3.88雼煬)搿� 雭岇柎鞓牳鞀惦媹雼�.

攵�氍鸽硠 霃欗枼:

  • 鞎勲⿺毽勾 歆�鞐� 毵れ稖鞚� 鞐办磮 雽�牍� 5% 歃濌皜頃� 2鞏� 1,310毵� 雼煬搿�, WD-40 氅�韹办湢歃�(+6%)鞕� 鞀ろ帢靺滊Μ鞀ろ姼 霛检澑(+9%)鞚� 瓴澑頄堨姷雼堧嫟.
  • EIMEA 毵れ稖鞚� 7% 歃濌皜頃� 1鞏� 7,380毵� 雼煬搿�, 臧曧暅 臧�瓴�/氙轨姢 氚� 氍茧焿 須岆车鞚� 3攵勱赴 頇橃湪 鞎呾灛毳� 靸侅噭頄堨姷雼堧嫟.
  • 鞎勳嫓鞎�-韮滍弶鞏� 歆�鞐潃 6,960毵� 雼煬搿� 瓯办潣 氤�霃欖澊 鞐嗢棃鞙茧┌, 鞀ろ帢靺滊Μ鞀ろ姼 攵�氍胳潣 鞕勲頃� 靹膘灔鞚� 旮绊儉 鞙犾氤挫垬 霛检澑鞚� 攵�歆勳潉 靸侅噭頄堨姷雼堧嫟.

鞛靸來儨響� 氚� 順勱笀頋愲: 顺勱笀鞚赌 5,170毵� 雼煬搿� 歃濌皜頄堨溂氅�, 鞓侅梾頇滊彊鞙茧 鞚疙暅 靾溗硠旮堨澏� 5,800毵� 雼煬鞓�鞀惦媹雼�. 齑� 攵�毂勲姅 9,580毵� 雼煬搿� 靾滊秬毂勲箘鞙潃 EBITDA鞚� 1氚� 氙鸽鞚措┌, 氇摖 瓿勳暯 臁瓣贝鞚� 於╈”頄堨姷雼堧嫟. 欤检＜ 頇橃洂鞚� 齑� 4,720毵� 雼煬搿�(氚半嫻旮� 3,750毵� 雼煬, 鞛愳偓欤� 毵れ瀰 970毵� 雼煬) 旮办〈 5,000毵� 雼煬 鞛愳偓欤� 毵れ瀰 鞀轨澑 甓岉暅鞚� 2026雲� 8鞗� 31鞚缄箤歆� 1雲� 鞐办灔霅橃棃鞙茧┌, 3,220毵� 雼煬臧� 雮晞 鞛堨姷雼堧嫟.

鞝勲灥鞝� 臁办箻: 鞚茧秬 頇堨紑鞏� 氚� 觳唽 敫岆灉霌�(鞛碃, 鞓侅梾甓� 氚� 氍错槙鞛愳偘 930毵� 雼煬)臧� 毵り皝鞓堨爼鞛愳偘鞙茧 攵勲霅橃柎 頃奠嫭 鞙犾氤挫垬 鞝滍拡 韽姼韽措Μ鞓れ棎 瓿勳啀 歆戩頃橁碃 鞛堨潓鞚� 雮橅儉雰堨姷雼堧嫟. 鞓侁淡 鞛愴殞靷姅 旮半姤韱淀檾毳� 鞙犽搿� 氤�瓴巾晿鞐� 氤搓碃毳� 臧勳唽頇旐枅鞀惦媹雼�.

臧赌鞚措崢鞀�/鞝勲: 瓴届榿歆勳潃 4x4 鞝勲灥 頂勲爤鞛勳泴韥ゼ 鞛檿鞚疙晿氅�, 55% 鞚挫儊鞚� 毵れ稖齑濎澊鞚惦瓿� 敫岆灉霌� 甑稌鞐� 雽�頃� 歆�靻嶌爜鞚� 韴瀽毳� 臧曥“頄堨姷雼堧嫟. 鞚疙攲霠堨澊靺�, 頇橃湪 氤�霃欖劚 氚� HCCP 毵り皝 鞁滌爯鞚� 欤检殧 甏�彀� 韽澑韸鸽 雮晞 鞛堨姷雼堧嫟.

WD-40 Company (NASDAQ : WDFC) a publi茅 des r茅sultats solides pour les neuf premiers mois de l鈥檈xercice 2025 (fin au 31 mai 2025), marqu茅s par une croissance du chiffre d鈥檃ffaires, une expansion des marges et un avantage fiscal exceptionnel.

Compte de r茅sultat : Les ventes nettes ont augment茅 de 5 % depuis le d茅but de l鈥檃nn茅e pour atteindre 456,5 millions de dollars (le seul T3 en hausse de 1 % 脿 156,9 millions), principalement gr芒ce 脿 la combinaison prix/mix et 脿 la reprise des volumes dans les produits de maintenance. La marge brute a progress茅 de 9 % pour atteindre 251,9 millions de dollars, faisant passer la marge brute 脿 55,2 % (+210 points de base) (marge T3 脿 56,1 %). Les charges op茅rationnelles ont augment茅 de 11 % (hausse des SG&A et de la publicit茅), mais le r茅sultat d鈥檈xploitation a tout de m锚me progress茅 de 5 % 脿 75,8 millions de dollars. Une lib茅ration de 11,9 millions de dollars li茅e 脿 une position fiscale incertaine a r茅duit le taux d鈥檌mposition effectif 脿 5,9 %, faisant bondir le r茅sultat net de 32 % 脿 69,8 millions de dollars et le BPA dilu茅 脿 5,13 dollars (contre 3,88).

Tendances par segment :

  • Chiffre d鈥檃ffaires Am茅riques en hausse de 5 % depuis le d茅but de l鈥檃nn茅e 脿 213,1 millions, soutenu par WD-40 Multi-Use (+6 %) et les gammes Specialist (+9 %).
  • Chiffre d鈥檃ffaires EIMEA en hausse de 7 % 脿 173,8 millions ; une forte combinaison prix/mix et une reprise des volumes ont compens茅 les vents contraires li茅s aux changes au T3.
  • Asie-Pacifique stable 脿 69,6 millions ; une croissance modeste dans le segment Specialist a compens茅 la faiblesse des autres lignes de maintenance.

Bilan & flux de tr茅sorerie : La tr茅sorerie a augment茅 脿 51,7 millions ; la tr茅sorerie nette g茅n茅r茅e par les op茅rations a 茅t茅 de 58,0 millions. La dette totale s鈥櫭﹍猫ve 脿 95,8 millions (levier net inf茅rieur 脿 1脳 EBITDA) ; tous les engagements ont 茅t茅 respect茅s. Les retours aux actionnaires ont totalis茅 47,2 millions (dividendes 37,5 millions ; rachats 9,7 millions). L鈥檃utorisation de rachat existante de 50 millions a 茅t茅 prolong茅e d鈥檜n an jusqu鈥檃u 31 ao没t 2026 ; il reste 32,2 millions disponibles.

Actions strat茅giques : Certaines marques de soins 脿 domicile et de nettoyage (stocks, goodwill et actifs incorporels d鈥檜ne valeur de 9,3 millions) ont 茅t茅 class茅es comme destin茅es 脿 la vente, signalant un focus continu sur le portefeuille principal de produits de maintenance. La filiale britannique a chang茅 sa devise fonctionnelle pour l鈥檈uro, simplifiant ainsi les rapports.

Pr茅visions / Perspectives : La direction a r茅affirm茅 son cadre strat茅gique 芦 quatre par quatre 禄, mettant l鈥檃ccent sur une marge brute sup茅rieure 脿 55 % et un investissement continu dans le d茅veloppement de la marque. L鈥檌nflation, la volatilit茅 des changes et le calendrier de la cession HCCP restent des points cl茅s 脿 surveiller.

WD-40 Company (NASDAQ: WDFC) meldete solide Ergebnisse f眉r das Gesch盲ftsjahr 2025 Q3 (neun Monate bis 31. Mai 2025), gepr盲gt von Umsatzwachstum, Margenausweitung und einem einmaligen Steuervorteil.

Ergebnisrechnung: Der Nettoumsatz stieg im laufenden Jahr um 5 % auf 456,5 Mio. USD (im Q3 allein +1 % auf 156,9 Mio. USD), haupts盲chlich getrieben durch Preis-/Mix-Effekte und Volumenr眉ckgewinnung bei Wartungsprodukten. Der Bruttogewinn kletterte um 9 % auf 251,9 Mio. USD, wodurch die Bruttomarge um 210 Basispunkte auf 55,2 % stieg (Q3-Marge 56,1 %). Die Betriebskosten wuchsen um 11 % (h枚here SG&A und Werbung), dennoch stieg das Betriebsergebnis um 5 % auf 75,8 Mio. USD. Eine Freisetzung von 11,9 Mio. USD aus einer unsicheren Steuerposition senkte den effektiven Steuersatz auf 5,9 %, was den Nettogewinn um 32 % auf 69,8 Mio. USD und das verw盲sserte Ergebnis je Aktie auf 5,13 USD (vorher 3,88) anhob.

Segmenttrends:

  • Umsatz Americas +5 % YTD auf 213,1 Mio. USD, gest眉tzt durch WD-40 Multi-Use (+6 %) und Specialist-Linien (+9 %).
  • EIMEA-Umsatz +7 % auf 173,8 Mio. USD; starke Preis-/Mix- und Volumenr眉ckgewinnung kompensierte W盲hrungsnachteile im Q3.
  • Asia-Pacific nahezu unver盲ndert bei 69,6 Mio. USD; moderates Wachstum bei Specialist kompensierte Schw盲che in anderen Wartungslinien.

Bilanz & Cashflow: Der Kassenbestand stieg auf 51,7 Mio. USD; der operative Nettocashflow betrug 58,0 Mio. USD. Die Gesamtschulden belaufen sich auf 95,8 Mio. USD (Nettohebel <1脳 EBITDA); alle Covenants wurden eingehalten. Die Aktion盲rsrenditen beliefen sich auf 47,2 Mio. USD (Dividenden 37,5 Mio.; Aktienr眉ckk盲ufe 9,7 Mio.). Die bestehende R眉ckkaufgenehmigung von 50 Mio. wurde um ein Jahr bis zum 31. August 2026 verl盲ngert; 32,2 Mio. sind noch verf眉gbar.

Strategische Ma脽nahmen: Bestimmte Homecare- und Reinigungsmarken (Inventar, Firmenwerte und immaterielle Verm枚genswerte im Wert von 9,3 Mio. USD) wurden als zur Ver盲u脽erung gehalten klassifiziert, was den anhaltenden Fokus auf das Kernportfolio von Wartungsprodukten signalisiert. Die britische Tochtergesellschaft wechselte die funktionale W盲hrung auf den Euro, um die Berichterstattung zu vereinfachen.

Ausblick: Das Management bekr盲ftigte seinen 鈥濾ier-mal-vier鈥�-Strategierahmen, mit Betonung auf einer Bruttomarge von 眉ber 55 % und fortgesetzten Investitionen in Markenaufbau. Inflation, Wechselkursvolatilit盲t und das Timing der HCCP-Ver盲u脽erung bleiben wichtige Beobachtungspunkte.

Positive
  • Gross margin expanded 210 bp YTD to 55.2 %, exceeding management鈥檚 long-term goal.
  • Net income and diluted EPS up 32 % YTD, supported by operating leverage and a $11.9 m tax benefit.
  • Operating cash flow of $58.0 million comfortably funded dividends and buybacks.
  • Americas and EIMEA segments delivered 5鈥�7 % revenue growth, demonstrating brand resilience despite macro headwinds.
  • Board extended $50 million share-repurchase plan to August 2026; $32.2 million still authorized.
Negative
  • Operating expenses rose 11 % YTD, outpacing sales and pressuring operating leverage.
  • Homecare & Cleaning Products revenue fell 11 %, and related assets are being sold, signaling weakness in that category.
  • EIMEA quarterly sales declined 5 % on currency pressure and softer distributor orders.
  • EPS boost heavily reliant on one-off tax reversal; underlying earnings growth is mid-single digit.
  • Total debt remains at $95.8 million; although manageable, interest expense still exceeds interest income.

Insights

TL;DR YTD revenue +5 %, margins >55 %, EPS boosted by $11.9 m tax release; core maintenance portfolio healthy, HCCP divestiture pending.

Assessment: The quarter reinforces WD-40鈥檚 pricing power and resilient demand for its maintenance brands. Gross margin surpassed the company鈥檚 long-term 55 % target, aided by easing input costs and favourable mix. Operating spend ran hot (+11 %) as the firm reinvests in marketing and digital, but leverage remains low and cash generation solid.
The $11.9 million tax reversal is non-recurring; adjusting for it, EPS growth is ~10 % YTD鈥攕till respectable. Americas and EIMEA delivered mid-single-digit growth; Asia-Pac is lagging. The decision to dispose of lower-margin HCCP assets should further sharpen focus and potentially lift margin profile, though divestiture proceeds and timing are still unknown.

Valuation impact: Results are modestly positive; consensus EPS estimates may tick up slightly, but investors will likely back out the tax item. Shares trade at a premium (~32脳 forward EPS); sustained gross-margin gains and incremental capital returns could justify the multiple.

TL;DR Clean quarter: steady sales, better margins, disciplined capital return; limited catalysts beyond tax windfall.

The print is constructive but not game-changing. Organic growth remains in the low-single digits; currency shaved ~1 % from YTD sales. The margin beat is encouraging; however, SG&A creep bears monitoring. Debt ladder is comfortable (no major maturities until 2027) and liquidity ample.

Strategically, exiting HCCP fits the long-standing 鈥榖lue and yellow can鈥� narrative, yet the assets are small (<3 % of sales). Primary risk is valuation stretch versus peers amid modest top-line growth. Absent further margin upside or accretive M&A, share performance may track dividend/buyback yield (~2 % cash + buyback).

WD-40 Company (NASDAQ: WDFC) ha riportato risultati solidi nei primi nove mesi dell'anno fiscale 2025 (terminati il 31 maggio 2025), evidenziando crescita dei ricavi, espansione dei margini e un beneficio fiscale una tantum.

Conto economico: Le vendite nette sono aumentate del 5% da inizio anno a 456,5 milioni di dollari (solo nel terzo trimestre +1% a 156,9 milioni di dollari), trainate principalmente da prezzo/mix e ripresa dei volumi nei prodotti per la manutenzione. Il margine lordo 猫 cresciuto del 9% a 251,9 milioni di dollari, portando il margine lordo a 55,2% (+210 punti base) (margine Q3 56,1%). Le spese operative sono aumentate dell'11% (a causa di maggiori SG&A e pubblicit脿), ma l'utile operativo 猫 comunque salito del 5% a 75,8 milioni di dollari. Un rilascio di 11,9 milioni di dollari relativo a una posizione fiscale incerta ha ridotto l'aliquota fiscale effettiva al 5,9%, facendo salire l'utile netto del 32% a 69,8 milioni di dollari e l'EPS diluito a 5,13 dollari (da 3,88).

Tendenze per segmento:

  • Ricavi Americas +5% da inizio anno a 213,1 milioni di dollari, supportati da WD-40 Multi-Use (+6%) e linee Specialist (+9%).
  • Ricavi EIMEA +7% a 173,8 milioni di dollari; forte prezzo/mix e recupero dei volumi hanno compensato le difficolt脿 valutarie del Q3.
  • Asia-Pacific sostanzialmente stabile a 69,6 milioni di dollari; moderata crescita nel segmento Specialist ha compensato la debolezza in altre linee di manutenzione.

Stato patrimoniale e flussi di cassa: La liquidit脿 猫 salita a 51,7 milioni di dollari; il flusso di cassa netto da attivit脿 operative 猫 stato di 58,0 milioni di dollari. Il debito totale 猫 pari a 95,8 milioni di dollari (leva netta inferiore a 1脳 EBITDA); tutti i covenant sono rispettati. I ritorni agli azionisti hanno totalizzato 47,2 milioni di dollari (dividendi 37,5 milioni; riacquisti 9,7 milioni). L'autorizzazione esistente per riacquisto di 50 milioni 猫 stata estesa di un anno fino al 31 agosto 2026; rimangono 32,2 milioni disponibili.

Azioni strategiche: Alcuni marchi di homecare e pulizia (inventario, avviamento e intangibili per 9,3 milioni di dollari) sono stati classificati come held for sale, segnalando un focus continuo sul portafoglio di prodotti core per la manutenzione. La controllata UK ha cambiato la valuta funzionale in euro, semplificando la reportistica.

Previsioni/Outlook: Il management ha ribadito il quadro strategico 鈥渜uattro per quattro鈥�, sottolineando l'obiettivo di un margine lordo superiore al 55% e il continuo investimento nel brand building. Inflazione, volatilit脿 valutaria e tempistica della cessione HCCP restano punti chiave da monitorare.

WD-40 Company (NASDAQ: WDFC) report贸 resultados s贸lidos en lo que va del a帽o para el tercer trimestre del a帽o fiscal 2025 (nueve meses terminados el 31 de mayo de 2025), destacando crecimiento en ingresos, expansi贸n de m谩rgenes y un beneficio fiscal extraordinario.

Estado de resultados: Las ventas netas aumentaron un 5% en lo que va del a帽o a 456.5 millones de d贸lares (solo en el tercer trimestre +1% a 156.9 millones), impulsadas principalmente por precio/mezcla y recuperaci贸n de volumen en productos de mantenimiento. La utilidad bruta subi贸 un 9% a 251.9 millones de d贸lares, elevando el margen bruto 210 puntos base a 55.2% (margen Q3 56.1%). Los gastos operativos crecieron un 11% (mayores SG&A y publicidad), pero el ingreso operativo avanz贸 un 5% a 75.8 millones. Una liberaci贸n de 11.9 millones de d贸lares relacionada con una posici贸n fiscal incierta redujo la tasa efectiva de impuestos al 5.9%, impulsando la utilidad neta un 32% a 69.8 millones y el EPS diluido a 5.13 d贸lares (vs. 3.88).

Tendencias por segmento:

  • Ingresos en Americas +5% YTD a 213.1 millones, apoyados por WD-40 Multi-Use (+6%) y l铆neas Specialist (+9%).
  • Ingresos en EIMEA +7% a 173.8 millones; fuerte precio/mezcla y recuperaci贸n de volumen compensaron los vientos en contra cambiarios del Q3.
  • Asia-Pac铆fico pr谩cticamente plano en 69.6 millones; crecimiento modesto en Specialist compens贸 debilidad en otras l铆neas de mantenimiento.

Balance y flujo de caja: El efectivo aument贸 a 51.7 millones; el flujo neto de operaciones fue de 58.0 millones. La deuda total es de 95.8 millones (apalancamiento neto <1脳 EBITDA); se cumplieron todos los convenios. Retornos a accionistas totalizaron 47.2 millones (dividendos 37.5 millones; recompras 9.7 millones). La autorizaci贸n existente para recompra de 50 millones se extendi贸 un a帽o hasta el 31 de agosto de 2026; quedan 32.2 millones disponibles.

Acciones estrat茅gicas: Algunas marcas de cuidado del hogar y limpieza (inventario, plusval铆a e intangibles por 9.3 millones) fueron clasificadas como held for sale, indicando un enfoque continuo en el portafolio principal de productos de mantenimiento. La filial del Reino Unido cambi贸 su moneda funcional al euro, simplificando la presentaci贸n de informes.

Perspectivas: La direcci贸n reafirm贸 su marco estrat茅gico cuatro por cuatro, enfatizando un margen bruto superior al 55% y la inversi贸n continua en construcci贸n de marca. La inflaci贸n, volatilidad cambiaria y el momento de la desinversi贸n de HCCP siguen siendo puntos clave a vigilar.

WD-40 Company (NASDAQ: WDFC)電� 2025 須岅硠鞐半弰 3攵勱赴(2025雲� 5鞗� 31鞚� 膦呺 9臧滌洈臧�) 瓴碃頃� 鞐办磮 雸勳爜 鞁れ爜鞚� 氚滍憸頄堨溂氅�, 毵れ稖 靹膘灔, 毵堨 頇曤寑 氚� 鞚柬殞靹� 靹戈笀 順滍儩鞚� 霊愲摐霟鞀惦媹雼�.

靻愳澋瓿勋偘靹�: 靾滊Г於滌潃 鞐办磮 雽�牍� 5% 歃濌皜頃� 4鞏� 5,650毵� 雼煬毳� 旮半頄堨溂氅�(3攵勱赴 雼弲鞙茧電� 1% 歃濌皜頃� 1鞏� 5,690毵� 雼煬), 欤茧 臧�瓴�/氙轨姢鞕� 鞙犾氤挫垬 鞝滍拡鞚� 氍茧焿 須岆车鞐� 頌橃瀰鞐堨姷雼堧嫟. 毵れ稖齑濎澊鞚奠潃 9% 歃濌皜頃� 2鞏� 5,190毵� 雼煬搿�, 毵れ稖齑濎澊鞚惦鞚� 210bp 靸侅姽頃� 55.2%(3攵勱赴 毵堨 56.1%)毳� 旮半頄堨姷雼堧嫟. 鞓侅梾牍勳毄鞚� 11% 歃濌皜(韺愲Г甏�毽箘 氚� 甏戧碃牍� 歃濌皜)頄堨溂雮� 鞓侅梾鞚挫澋鞚� 5% 歃濌皜頃� 7,580毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 攵堩檿鞁ろ暅 靹鸽 鞙勳箻 頃挫唽搿� 鞚疙暅 1,190毵� 雼煬鞚� 鞚柬殞靹� 靹戈笀 順滍儩鞚� 鞙犿毃靹胳湪鞚� 5.9%搿� 雮稊鞏� 靾滌澊鞚奠潉 32% 歃濌皜頃� 6,980毵� 雼煬 氚� 頋劃 欤茧嫻靾滌澊鞚�(EPS)鞚� 5.13 雼煬(旮办〈 3.88雼煬)搿� 雭岇柎鞓牳鞀惦媹雼�.

攵�氍鸽硠 霃欗枼:

  • 鞎勲⿺毽勾 歆�鞐� 毵れ稖鞚� 鞐办磮 雽�牍� 5% 歃濌皜頃� 2鞏� 1,310毵� 雼煬搿�, WD-40 氅�韹办湢歃�(+6%)鞕� 鞀ろ帢靺滊Μ鞀ろ姼 霛检澑(+9%)鞚� 瓴澑頄堨姷雼堧嫟.
  • EIMEA 毵れ稖鞚� 7% 歃濌皜頃� 1鞏� 7,380毵� 雼煬搿�, 臧曧暅 臧�瓴�/氙轨姢 氚� 氍茧焿 須岆车鞚� 3攵勱赴 頇橃湪 鞎呾灛毳� 靸侅噭頄堨姷雼堧嫟.
  • 鞎勳嫓鞎�-韮滍弶鞏� 歆�鞐潃 6,960毵� 雼煬搿� 瓯办潣 氤�霃欖澊 鞐嗢棃鞙茧┌, 鞀ろ帢靺滊Μ鞀ろ姼 攵�氍胳潣 鞕勲頃� 靹膘灔鞚� 旮绊儉 鞙犾氤挫垬 霛检澑鞚� 攵�歆勳潉 靸侅噭頄堨姷雼堧嫟.

鞛靸來儨響� 氚� 順勱笀頋愲: 顺勱笀鞚赌 5,170毵� 雼煬搿� 歃濌皜頄堨溂氅�, 鞓侅梾頇滊彊鞙茧 鞚疙暅 靾溗硠旮堨澏� 5,800毵� 雼煬鞓�鞀惦媹雼�. 齑� 攵�毂勲姅 9,580毵� 雼煬搿� 靾滊秬毂勲箘鞙潃 EBITDA鞚� 1氚� 氙鸽鞚措┌, 氇摖 瓿勳暯 臁瓣贝鞚� 於╈”頄堨姷雼堧嫟. 欤检＜ 頇橃洂鞚� 齑� 4,720毵� 雼煬搿�(氚半嫻旮� 3,750毵� 雼煬, 鞛愳偓欤� 毵れ瀰 970毵� 雼煬) 旮办〈 5,000毵� 雼煬 鞛愳偓欤� 毵れ瀰 鞀轨澑 甓岉暅鞚� 2026雲� 8鞗� 31鞚缄箤歆� 1雲� 鞐办灔霅橃棃鞙茧┌, 3,220毵� 雼煬臧� 雮晞 鞛堨姷雼堧嫟.

鞝勲灥鞝� 臁办箻: 鞚茧秬 頇堨紑鞏� 氚� 觳唽 敫岆灉霌�(鞛碃, 鞓侅梾甓� 氚� 氍错槙鞛愳偘 930毵� 雼煬)臧� 毵り皝鞓堨爼鞛愳偘鞙茧 攵勲霅橃柎 頃奠嫭 鞙犾氤挫垬 鞝滍拡 韽姼韽措Μ鞓れ棎 瓿勳啀 歆戩頃橁碃 鞛堨潓鞚� 雮橅儉雰堨姷雼堧嫟. 鞓侁淡 鞛愴殞靷姅 旮半姤韱淀檾毳� 鞙犽搿� 氤�瓴巾晿鞐� 氤搓碃毳� 臧勳唽頇旐枅鞀惦媹雼�.

臧赌鞚措崢鞀�/鞝勲: 瓴届榿歆勳潃 4x4 鞝勲灥 頂勲爤鞛勳泴韥ゼ 鞛檿鞚疙晿氅�, 55% 鞚挫儊鞚� 毵れ稖齑濎澊鞚惦瓿� 敫岆灉霌� 甑稌鞐� 雽�頃� 歆�靻嶌爜鞚� 韴瀽毳� 臧曥“頄堨姷雼堧嫟. 鞚疙攲霠堨澊靺�, 頇橃湪 氤�霃欖劚 氚� HCCP 毵り皝 鞁滌爯鞚� 欤检殧 甏�彀� 韽澑韸鸽 雮晞 鞛堨姷雼堧嫟.

WD-40 Company (NASDAQ : WDFC) a publi茅 des r茅sultats solides pour les neuf premiers mois de l鈥檈xercice 2025 (fin au 31 mai 2025), marqu茅s par une croissance du chiffre d鈥檃ffaires, une expansion des marges et un avantage fiscal exceptionnel.

Compte de r茅sultat : Les ventes nettes ont augment茅 de 5 % depuis le d茅but de l鈥檃nn茅e pour atteindre 456,5 millions de dollars (le seul T3 en hausse de 1 % 脿 156,9 millions), principalement gr芒ce 脿 la combinaison prix/mix et 脿 la reprise des volumes dans les produits de maintenance. La marge brute a progress茅 de 9 % pour atteindre 251,9 millions de dollars, faisant passer la marge brute 脿 55,2 % (+210 points de base) (marge T3 脿 56,1 %). Les charges op茅rationnelles ont augment茅 de 11 % (hausse des SG&A et de la publicit茅), mais le r茅sultat d鈥檈xploitation a tout de m锚me progress茅 de 5 % 脿 75,8 millions de dollars. Une lib茅ration de 11,9 millions de dollars li茅e 脿 une position fiscale incertaine a r茅duit le taux d鈥檌mposition effectif 脿 5,9 %, faisant bondir le r茅sultat net de 32 % 脿 69,8 millions de dollars et le BPA dilu茅 脿 5,13 dollars (contre 3,88).

Tendances par segment :

  • Chiffre d鈥檃ffaires Am茅riques en hausse de 5 % depuis le d茅but de l鈥檃nn茅e 脿 213,1 millions, soutenu par WD-40 Multi-Use (+6 %) et les gammes Specialist (+9 %).
  • Chiffre d鈥檃ffaires EIMEA en hausse de 7 % 脿 173,8 millions ; une forte combinaison prix/mix et une reprise des volumes ont compens茅 les vents contraires li茅s aux changes au T3.
  • Asie-Pacifique stable 脿 69,6 millions ; une croissance modeste dans le segment Specialist a compens茅 la faiblesse des autres lignes de maintenance.

Bilan & flux de tr茅sorerie : La tr茅sorerie a augment茅 脿 51,7 millions ; la tr茅sorerie nette g茅n茅r茅e par les op茅rations a 茅t茅 de 58,0 millions. La dette totale s鈥櫭﹍猫ve 脿 95,8 millions (levier net inf茅rieur 脿 1脳 EBITDA) ; tous les engagements ont 茅t茅 respect茅s. Les retours aux actionnaires ont totalis茅 47,2 millions (dividendes 37,5 millions ; rachats 9,7 millions). L鈥檃utorisation de rachat existante de 50 millions a 茅t茅 prolong茅e d鈥檜n an jusqu鈥檃u 31 ao没t 2026 ; il reste 32,2 millions disponibles.

Actions strat茅giques : Certaines marques de soins 脿 domicile et de nettoyage (stocks, goodwill et actifs incorporels d鈥檜ne valeur de 9,3 millions) ont 茅t茅 class茅es comme destin茅es 脿 la vente, signalant un focus continu sur le portefeuille principal de produits de maintenance. La filiale britannique a chang茅 sa devise fonctionnelle pour l鈥檈uro, simplifiant ainsi les rapports.

Pr茅visions / Perspectives : La direction a r茅affirm茅 son cadre strat茅gique 芦 quatre par quatre 禄, mettant l鈥檃ccent sur une marge brute sup茅rieure 脿 55 % et un investissement continu dans le d茅veloppement de la marque. L鈥檌nflation, la volatilit茅 des changes et le calendrier de la cession HCCP restent des points cl茅s 脿 surveiller.

WD-40 Company (NASDAQ: WDFC) meldete solide Ergebnisse f眉r das Gesch盲ftsjahr 2025 Q3 (neun Monate bis 31. Mai 2025), gepr盲gt von Umsatzwachstum, Margenausweitung und einem einmaligen Steuervorteil.

Ergebnisrechnung: Der Nettoumsatz stieg im laufenden Jahr um 5 % auf 456,5 Mio. USD (im Q3 allein +1 % auf 156,9 Mio. USD), haupts盲chlich getrieben durch Preis-/Mix-Effekte und Volumenr眉ckgewinnung bei Wartungsprodukten. Der Bruttogewinn kletterte um 9 % auf 251,9 Mio. USD, wodurch die Bruttomarge um 210 Basispunkte auf 55,2 % stieg (Q3-Marge 56,1 %). Die Betriebskosten wuchsen um 11 % (h枚here SG&A und Werbung), dennoch stieg das Betriebsergebnis um 5 % auf 75,8 Mio. USD. Eine Freisetzung von 11,9 Mio. USD aus einer unsicheren Steuerposition senkte den effektiven Steuersatz auf 5,9 %, was den Nettogewinn um 32 % auf 69,8 Mio. USD und das verw盲sserte Ergebnis je Aktie auf 5,13 USD (vorher 3,88) anhob.

Segmenttrends:

  • Umsatz Americas +5 % YTD auf 213,1 Mio. USD, gest眉tzt durch WD-40 Multi-Use (+6 %) und Specialist-Linien (+9 %).
  • EIMEA-Umsatz +7 % auf 173,8 Mio. USD; starke Preis-/Mix- und Volumenr眉ckgewinnung kompensierte W盲hrungsnachteile im Q3.
  • Asia-Pacific nahezu unver盲ndert bei 69,6 Mio. USD; moderates Wachstum bei Specialist kompensierte Schw盲che in anderen Wartungslinien.

Bilanz & Cashflow: Der Kassenbestand stieg auf 51,7 Mio. USD; der operative Nettocashflow betrug 58,0 Mio. USD. Die Gesamtschulden belaufen sich auf 95,8 Mio. USD (Nettohebel <1脳 EBITDA); alle Covenants wurden eingehalten. Die Aktion盲rsrenditen beliefen sich auf 47,2 Mio. USD (Dividenden 37,5 Mio.; Aktienr眉ckk盲ufe 9,7 Mio.). Die bestehende R眉ckkaufgenehmigung von 50 Mio. wurde um ein Jahr bis zum 31. August 2026 verl盲ngert; 32,2 Mio. sind noch verf眉gbar.

Strategische Ma脽nahmen: Bestimmte Homecare- und Reinigungsmarken (Inventar, Firmenwerte und immaterielle Verm枚genswerte im Wert von 9,3 Mio. USD) wurden als zur Ver盲u脽erung gehalten klassifiziert, was den anhaltenden Fokus auf das Kernportfolio von Wartungsprodukten signalisiert. Die britische Tochtergesellschaft wechselte die funktionale W盲hrung auf den Euro, um die Berichterstattung zu vereinfachen.

Ausblick: Das Management bekr盲ftigte seinen 鈥濾ier-mal-vier鈥�-Strategierahmen, mit Betonung auf einer Bruttomarge von 眉ber 55 % und fortgesetzten Investitionen in Markenaufbau. Inflation, Wechselkursvolatilit盲t und das Timing der HCCP-Ver盲u脽erung bleiben wichtige Beobachtungspunkte.

&nbsp;

As filed with the Securities and Exchange Commission on July&nbsp;10, 2025

Registration No.&nbsp;333-

&nbsp;

&nbsp;

&nbsp;

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

&nbsp;

FORM&nbsp;S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

&nbsp;

&nbsp;

HELIUS MEDICAL TECHNOLOGIES,&nbsp;INC.
(Exact name of registrant as specified in its charter)

&nbsp;

&nbsp;

Delaware &nbsp; 36-4787690

(State or other jurisdiction of
incorporation or organization)

 &nbsp; (I.R.S. Employer
Identification No.)
&nbsp; &nbsp;

642 Newtown Yardley Road, Suite&nbsp;100
Newtown, Pennsylvania

 &nbsp; 18940
(Address of principal executive offices) &nbsp; (Zip code)

&nbsp;

Helius Medical Technologies,&nbsp;Inc. 2022 Equity Incentive Plan

(Full title of the plan)

&nbsp;

Dane C. Andreeff
President and Chief Executive Officer
Helius Medical Technologies,&nbsp;Inc.
642 Newtown Yardley Road, Suite&nbsp;100
Newtown, Pennsylvania 18940
(215) 944-6100
(Name, address, and telephone number, including area code, of agent for service)

&nbsp;

&nbsp;

Copy to:

&nbsp;

Phillip D. Torrence,&nbsp;Esq.
Jeffrey Kuras,&nbsp;Esq.
Honigman LLP
650 Trade Center Way, Suite&nbsp;200
Kalamazoo, Michigan 49002-0402
(269) 337-7700

&nbsp;

&nbsp;

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.

&nbsp;

&nbsp;Large accelerated filer &nbsp; ¨ &nbsp; Accelerated filer &nbsp; ¨
&nbsp; &nbsp; &nbsp; &nbsp;
Non-accelerated filer &nbsp; x &nbsp; Smaller reporting company &nbsp; x
&nbsp; &nbsp; &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; Emerging growth company &nbsp; ¨

&nbsp;

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. ¨

&nbsp;

&nbsp;

&nbsp;

&nbsp;

&nbsp;

EXPLANATORY NOTE

&nbsp;

2022 Equity Incentive Plan

&nbsp;

This Registration Statement on Form&nbsp;S-8 is being filed by Helius Medical Technologies,&nbsp;Inc. (the &ldquo;Company,&rdquo; the &ldquo;Registrant,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; or &ldquo;our&rdquo;), for the purpose of registering an additional 240,000 shares of Class&nbsp;A common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), that may be issued pursuant to Awards (as defined in the 2022 Equity Incentive Plan) under the Helius Medical Technologies,&nbsp;Inc. 2022 Equity Incentive Plan, as amended (the &ldquo;2022 Equity Incentive Plan&rdquo;).

&nbsp;

Pursuant to General Instruction E to Form&nbsp;S-8, this Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Company on Form&nbsp;S-8 relating to the 2022 Equity Incentive Plan, respectively, are effective, and the Company&rsquo;s Registration Statements on Form&nbsp;S-8 previously filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) on May&nbsp;31, 2022 (File No. 333-265324), January&nbsp;19, 2023 (File No. 333-269305), July&nbsp;24, 2024 (File No. 333-280978) and March&nbsp;25, 2025 (File No. 333-286100) registering shares of Common Stock issuable under the 2022 Equity Incentive Plan are incorporated by reference and made part of this Registration Statement, except as amended hereby.

&nbsp;

PART&nbsp;I

&nbsp;

INFORMATION REQUIRED IN THE SECTION&nbsp;10(a)&nbsp;PROSPECTUS

&nbsp;

The information specified in Part&nbsp;I of Form&nbsp;S-8 is omitted from this Registration Statement in accordance with the provisions of Rule&nbsp;428 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and the introductory note to Part&nbsp;I of Form&nbsp;S-8. The documents containing the information specified in Part&nbsp;I of Form&nbsp;S-8 will be delivered to the participants in the plan covered by this Registration Statement as specified by Rule&nbsp;428(b)(1)&nbsp;under the Securities Act.

&nbsp;

&nbsp;

&nbsp;

PART&nbsp;II

&nbsp;

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

&nbsp;

Item 3. Incorporation of Documents by Reference.

&nbsp;

The following documents filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) by the Registrant are hereby incorporated by reference in this Registration Statement:

&nbsp;

a)the Registrant&rsquo;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2024 filed with the Commission on March&nbsp;25, 2025;

&nbsp;

b)the Registrant&rsquo;s Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2025 filed with the Commission on May&nbsp;1, 2025;

&nbsp;

c)the Registrant&rsquo;s Current Reports on Form&nbsp;8-K filed with the Commission on January&nbsp;15, 2025, January&nbsp;24, 2025, February&nbsp;7, 2025, April&nbsp;4, 2025, April&nbsp;22, 2025, April&nbsp;25, 2025, April&nbsp;30, 2025, May&nbsp;23, 2025, June&nbsp;4, 2025, June&nbsp;20, 2025, June&nbsp;23, 2025, June&nbsp;27, 2025, July&nbsp;7, 2025 and July&nbsp;9, 2025 and

&nbsp;

d)the description of the Registrant&rsquo;s Common Stock contained in the Registrant&rsquo;s Form&nbsp;8-A (File No.&nbsp;001-38445) filed with the Commission on April&nbsp;4, 2018, as amended by the description of the Common Stock contained in Exhibit&nbsp;4.7 to the Registrant&rsquo;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2020, and as further amended by any subsequent amendment or report filed for the purpose of updating such description.

&nbsp;

In addition, all documents the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d)&nbsp;of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), after the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form&nbsp;8-K, unless, and to the extent, specified in any such Current Report on Form&nbsp;8-K.

&nbsp;

Any statement herein or contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

&nbsp;

Item 4. Description of Securities.

&nbsp;

Not applicable.

&nbsp;

Item 5. Interests of Named Experts and Counsel.

&nbsp;

Not applicable.

&nbsp;

Item 6. Indemnification of Directors and Officers.

&nbsp;

We are incorporated under the laws of the State of Delaware. Section&nbsp;102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

&nbsp;

&nbsp;

&nbsp;

Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines upon application that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

&nbsp;

As permitted by the Delaware General Corporation Law, our amended and restated bylaws provide that: (1)&nbsp;we are required to indemnify our directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law; (2)&nbsp;we may, in our discretion, indemnify our other officers, employees and agents as set forth in the Delaware General Corporation Law; (3)&nbsp;we are required, upon satisfaction of certain conditions, to advance all expenses incurred by our directors and executive officers in connection with certain legal proceedings; (4)&nbsp;the rights conferred in the bylaws are not exclusive; (5)&nbsp;we are authorized to enter into indemnification agreements with our directors, officers, employees and agents; and (6)&nbsp;we may secure insurance on behalf of any director, officer, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law.

&nbsp;

Indemnification Agreements

&nbsp;

We have entered into indemnification agreements with our directors and officers. These agreements provide broader indemnity rights than those provided under the Delaware General Corporation Law and the Registrant&rsquo;s certificate of incorporation, as amended. The indemnification agreements are not intended to deny or otherwise limit third-party or derivative suits against us or our directors or officers, but to the extent a director or officer were entitled to indemnity or contribution under the indemnification agreement, the financial burden of a third-party suit would be borne by us, and we would not benefit from derivative recoveries against the director or officer. Such recoveries would accrue to our benefit but would be offset by our obligations to the director or officer under the indemnification agreement.

&nbsp;

Insurance Policy

&nbsp;

We maintain a directors&rsquo; and officers&rsquo; liability insurance policy. The policy insures directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and officers. The policy contains various exclusions.

&nbsp;

The foregoing summaries are not intended to be exhaustive and are qualified in their entirety by reference to the complete text of the statute, the Registrant&rsquo;s certificate of incorporation, as amended and the agreements referred to above and are qualified in their entirety by reference thereto.

&nbsp;

Item 7. Exemption from Registration Claimed.

&nbsp;

Not applicable.

&nbsp;

&nbsp;

&nbsp;

Item 8. Exhibits.

&nbsp;

EXHIBIT&nbsp;INDEX

&nbsp;

The following exhibits are filed as part of this registration statement.

&nbsp;

INDEX TO EXHIBITS

&nbsp;

Exhibit
Number		 &nbsp; Description
&nbsp; &nbsp; &nbsp;
4.1 &nbsp; Certificate of Conversion filed with the Delaware Secretary of State on July&nbsp;18, 2018 (incorporated by reference to Exhibit&nbsp;3.1 to the Form&nbsp;10-Q filed August&nbsp;9, 2018)
&nbsp; &nbsp; &nbsp;
4.2 &nbsp; Certificate of Incorporation, as corrected (incorporated by reference to Exhibit&nbsp;3.1 to the Form&nbsp;8-K filed October&nbsp;30, 2018)
&nbsp; &nbsp; &nbsp;
4.3 &nbsp; Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit&nbsp;3.1 to the Form&nbsp;8-K filed on December&nbsp;31, 2020)
&nbsp; &nbsp; &nbsp;
4.4 &nbsp; Certificate of Designation of the Series&nbsp;B Preferred Stock of the Registrant (incorporated by reference to Exhibit&nbsp;3.1(a)&nbsp;to the Registration Statement on Form&nbsp;8-A, filed March&nbsp;24, 2023)
&nbsp; &nbsp; &nbsp;
4.5 &nbsp; Corrected Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit&nbsp;3.1 to the Form&nbsp;8-K filed August&nbsp;16, 2023)
&nbsp; &nbsp; &nbsp;
4.6 &nbsp; Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit&nbsp;3.1 to the Form&nbsp;8-K filed April&nbsp;30, 2025)
&nbsp; &nbsp; &nbsp;
4.7 &nbsp; Second Amended and Restated Bylaws (incorporated by reference to Exhibit&nbsp;3.1 to the Form&nbsp;8-K filed March&nbsp;15, 2024)
&nbsp; &nbsp; &nbsp;
4.8 &nbsp; Helius Medical Technologies,&nbsp;Inc. 2022 Equity Incentive Plan (incorporated by reference to Exhibit&nbsp;10.1 to the Form&nbsp;8-K filed February&nbsp;18, 2022)
&nbsp; &nbsp; &nbsp;
4.9 &nbsp; Helius Medical Technologies,&nbsp;Inc. 2022 Equity Incentive Plan Form&nbsp;of Stock Option Agreement (incorporated by reference to Exhibit&nbsp;10.3 to the Form&nbsp;8-K filed February&nbsp;18, 2022)
&nbsp; &nbsp; &nbsp;
4.10 &nbsp; Amendment to the Helius Medical Technologies,&nbsp;Inc. 2022 Equity Incentive Plan (incorporated by reference to Exhibit&nbsp;10.1 to the Form&nbsp;8-K filed June&nbsp;28, 2024)
&nbsp; &nbsp; &nbsp;
4.11* &nbsp; Second Amendment to the Helius Medical Technologies,&nbsp;Inc. 2022 Equity Incentive Plan
&nbsp; &nbsp; &nbsp;
5.1* &nbsp; Opinion of Honigman LLP
&nbsp; &nbsp; &nbsp;
23.1* &nbsp; Consent of Baker Tilly US, LLP
&nbsp; &nbsp; &nbsp;
23.2* &nbsp; Consent of Honigman LLP (included in its opinion filed as Exhibit&nbsp;5.1 to this Registration Statement)
&nbsp; &nbsp; &nbsp;
24.1* &nbsp; Power of Attorney (included after the signature of the Registrant contained on Signature Page&nbsp;of this Registration Statement)
&nbsp; &nbsp; &nbsp;
107* &nbsp; Filing Fee Table

&nbsp;

*Filed herewith.

&nbsp;

&nbsp;

&nbsp;

Item 9. Undertakings.

&nbsp;

(a) The Registrant hereby undertakes:

&nbsp;

&nbsp; (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;

&nbsp; (i) To include any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act of 1933;
&nbsp; &nbsp; &nbsp;
&nbsp; (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Filing Fee Tables&rdquo; or &ldquo;Calculation of Registration Fee&rdquo; table, as applicable, in the effective Registration Statement;
&nbsp; &nbsp; &nbsp;
&nbsp; (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

&nbsp;

&nbsp; provided, however, that paragraphs (a)(1)(i)&nbsp;and (a)(1)(ii)&nbsp;do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement; and

&nbsp;

&nbsp; (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
&nbsp; &nbsp; &nbsp;
&nbsp; (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;

(b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant&rsquo;s annual report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to Section&nbsp;15(d)&nbsp;of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

&nbsp;

&nbsp;

&nbsp;

&nbsp;

SIGNATURES

&nbsp;

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&nbsp;S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, hereunto duly authorized, in the City of Newtown, State of Pennsylvania, on July&nbsp;10, 2025.

&nbsp;

&nbsp; Helius Medical Technologies,&nbsp;Inc.
&nbsp; &nbsp;
&nbsp; By: /s/ Dane C. Andreeff
&nbsp; &nbsp; Name: Dane C. Andreeff
&nbsp; &nbsp; Title: President and Chief Executive Officer

&nbsp;

&nbsp;

&nbsp;

&nbsp;

POWER OF ATTORNEY

&nbsp;

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dane C. Andreeff and Jeffrey S. Mathiesen as his or her true and lawful attorneys-in-fact and agents with full power of substitution, severally, for him in any and all capacities, to sign the Registration Statement on Form&nbsp;S-8 of Helius Medical Technologies,&nbsp;Inc., and any or all amendments (including post-effective amendments thereto), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

&nbsp;

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

&nbsp;

Signature &nbsp; Title &nbsp; Date
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
/s/ Dane C. Andreeff &nbsp; President, Chief Executive Officer &nbsp; July&nbsp;10, 2025
Dane C. Andreeff &nbsp; (Principal Executive Officer) and Director &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
/s/ Jeffrey S. Mathiesen &nbsp; Chief Financial Officer &nbsp; July&nbsp;10, 2025
Jeffrey S. Mathiesen &nbsp; (Principal Financial Officer and Principal Accounting Officer),
Treasurer, Secretary and Director		 &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
/s/ Paul Buckman &nbsp; Director &nbsp; July&nbsp;10, 2025
Paul Buckman &nbsp; &nbsp; &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
/s/ Blane Walter &nbsp; Director &nbsp; July&nbsp;10, 2025
Blane Walter &nbsp; &nbsp; &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
/s/ Sherrie Perkins &nbsp; Director &nbsp; July&nbsp;10, 2025
Sherrie Perkins &nbsp; &nbsp; &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
/s/ Edward M. Straw &nbsp; Director &nbsp; July&nbsp;10, 2025
Edward M. Straw &nbsp; &nbsp; &nbsp; &nbsp;

&nbsp;

&nbsp;

&nbsp;

Source:

FAQ

How much did WDFC revenue grow in FY-2025 YTD?

Net sales increased 5 % to $456.5 million for the nine months ended 31-May-2025.

What drove WD-40 Company's EPS increase?

Diluted EPS rose to $5.13 mainly due to higher gross margin and a $11.9 million tax benefit.

Which segments contributed most to growth?

The Americas (+5 %) and EIMEA (+7 %) segments delivered the bulk of revenue gains; Asia-Pacific was flat.

What is the status of the Homecare & Cleaning Products business?

Assets worth $9.3 million are classified as held for sale as management focuses on core maintenance brands.

How much authorization remains under the share-repurchase plan?

WD-40 has $32.2 million remaining after repurchasing 39,000 shares for $9.7 million YTD.

What dividend was declared after quarter-end?

On 17-Jun-2025 the Board declared a $0.94 per-share cash dividend payable 31-Jul-2025.
Stock HSDT logo
Helius Med Technologies Inc

NASDAQ:HSDT

HSDT Rankings

#11137 Ranked by Market Cap
N/A Ranked by Dividends

HSDT Latest News

Jul 21, 2025
Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS庐 Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
Jul 9, 2025
Helius Medical Technologies, Inc. Compliant with Nasdaq鈥檚 Continued Listing Requirements
Jun 27, 2025
Helius Medical Technologies Announces Reverse Stock Split
Jun 16, 2025
Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS庐) Device
Jun 12, 2025
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting

HSDT Latest SEC Filings

Jul 21, 2025
[8-K] Helius Medical Technologies, Inc. Reports Material Event
Jul 9, 2025
[8-K] Helius Medical Technologies, Inc. Reports Material Event
Jul 7, 2025
[8-K] Helius Medical Technologies, Inc. Reports Material Event
Jul 7, 2025
[424B5] Helius Medical Technologies, Inc. Prospectus Supplement (Debt Securities)
Jul 3, 2025
[Form 4] Helius Medical Technologies, Inc. Insider Trading Activity

HSDT Stock Data

5.14M
672.94k
0.53%
6.63%
0.34%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
United States
NEWTOWN